Inactive Instrument

COSMO Pharmaceuticals SA Share Price Swiss Exchange

Equities

LU1202320294

Pharmaceuticals

End-of-day quote Swiss Exchange
- CHF - Intraday chart for COSMO Pharmaceuticals SA

Financials

Sales 2024 * 264M 286M 256M 23.83B Sales 2025 * 242M 262M 235M 21.86B Capitalization 1.19B 1.29B 1.16B 108B
Net income 2024 * 130M 141M 126M 11.75B Net income 2025 * 66M 71.48M 64.05M 5.96B EV / Sales 2024 * 4.11 x
Net cash position 2024 * 112M 121M 108M 10.1B Net cash position 2025 * 220M 238M 213M 19.87B EV / Sales 2025 * 4.03 x
P/E ratio 2024 *
9.49 x
P/E ratio 2025 *
12.9 x
Employees -
Yield 2024 *
2.87%
Yield 2025 *
1.58%
Free-Float 44.36%
More Fundamentals * Assessed data

Latest transcript on COSMO Pharmaceuticals SA

Managers TitleAgeSince
Director of Finance/CFO 52 01/16/01
Chairman 61 01/06/01
Chief Tech/Sci/R&D Officer 54 -
Members of the board TitleAgeSince
Founder 69 01/97/01
Director/Board Member 69 01/12/01
Chairman 61 01/06/01
More insiders
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
More about the company